Pinteon Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2014-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.pinteon.com
Safety and Tolerability of PNT001 in Patients With Acute Traumatic Brain Injury (TBI)
Phase 1
Terminated
- Conditions
- Traumatic Brain Injury
- Interventions
- Biological: %5 dextrose for infusionBiological: PNT001
- First Posted Date
- 2020-12-21
- Last Posted Date
- 2022-06-29
- Lead Sponsor
- Pinteon Therapeutics, Inc
- Target Recruit Count
- 1
- Registration Number
- NCT04677829
- Locations
- 🇺🇸
Penn Presbyterian Medical Center, Philadelphia, Pennsylvania, United States
Safety and Tolerability of PNT001 in Healthy Adults
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: PlaceboBiological: PNT001
- First Posted Date
- 2019-09-19
- Last Posted Date
- 2021-02-23
- Lead Sponsor
- Pinteon Therapeutics, Inc
- Target Recruit Count
- 49
- Registration Number
- NCT04096287
- Locations
- 🇺🇸
Pacific Research Network, Inc., San Diego, California, United States
🇺🇸Woodland Research Northwest, Rogers, Arkansas, United States
🇺🇸Hassman Research Institute, Marlton, New Jersey, United States
© Copyright 2025. All Rights Reserved by MedPath